Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Catheter based renal denervation (CRD) in humans represents a promising new treatment of
resistant hypertension. CRD is currently investigated as a treatment option in patients with
resistant hypertension defined as at least 3 antihypertensive drugs (including a diuretic) in
a randomized, sham-controlled, multicenter trial in Denmark (ReSet). In ReSet, patients are
randomized to either CRD or a sham procedure with 6 months follow up. The mechanisms by which
CRD reduce blood pressure are only partly understood and the interaction between renal
sympathetic nerves and nitric oxide (NO) has not been investigated in humans.
To Study the interaction between NO and renal sympathetic nerves, we designed the present
substudy, where the effects of NO-inhibition on renal, hemodynamic and hormonal variables are
studied before and after CRD.